MedTrace Logo

Stability of the Microbiome in IBD and IBS

NCT03395548 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-08-11

No results posted yet for this study

Summary

In this study the investigators aim to investigate the changes of the intestinal microbiome in three different cohorts (IBD, IBS, healthy) after applying the uniform disruptive factor of osmotic diarrhea induced by macrogol. The investigators hypothesis is that ill people will show more severe changes of the microbiome than healthy people and that these changes persist longer.

Conditions

  • Microbiota

Interventions

DRUG

Macrogol

Used drug: Macrogol (osmotic laxative)

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Andreas Blesl, MD · Medical University of Graz

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-25
Primary Completion
2020-05-01
Completion
2020-05-01

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03395548 on ClinicalTrials.gov